BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We have furnished herewith newspaper clippings of Un-audited Standalone Financial Results of the Company for the 1st quarter ended June 30, 2023, and published in the newspapers, namely, Makkal Kural (Tamil edition) Business Standard (English edition) on Saturday, August 12, 2023. BAFNA PHARMACEUTICALS LTD. - 532989 - Financial Results For The Quarter Ended June 30, 2023.
the Board of Director of Bafna Pharmaceuticals Limited approved the Financial results for the quarter ended June 30, 2023. BAFNA PHARMACEUTICALS LTD. - 532989 - Delay In Submission Of Related Party Transactions For The Year Ended March 31, 2023.
The Board noted the issue of non-compliance with the Regulation 23(9) of SEBI (LODR) Regulations, 2015 BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholder Meeting - AGM On Friday, September 22, 2023.
the 28th Annual General Meeting of the Members of the Company will be held on Friday, September 22, 2023, at 10:25 am IST, through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM). BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Approval Of Financials For The Quarter Ended June 30, 2023
We wish to inform that at the meeting of the Board of Directors of the Company held today i.e., August 11, 2023, Friday, the results for the quarter ended on June 30, 2023, duly reviewed and recommended by the Audit Committee, inter-alia, has been considered and approved by the Board of Directors of the Company. BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Approval Of Q1 FY24 Financial Results.
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 ,inter alia, to consider and approve the Un-Audited Standalone Financial Results of the Company for the first quarter of FY24 ended June 30, 2023, together with the 'Limited Review Report' for the said period. BAFNA PHARMACEUTICALS LTD. - 532989 - Non-Applicability Of Declaration Of In Terms Of Regulation 32 Of SEBI (LODR) Regulations, 2015.
the Statement of Deviation and Variation of proceeds of Public Issue, Right Issue, Preferential Issue, Qualified Institutional Placement, etc. required to be submitted in terms of Regulation 32 of SEBI (LODR) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, is not applicable to Bafna Pharmaceuticals Limited (the Company) for the quarter ended June 30, 2023. BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We enclosed herewith a certificate dated July 07, 2023, received from Cameo Corporate Services Limited, the Registrar and Share Transfer Agent (RTA) of the Company, confirming dematerialization of share certificates during the quarter ended June 30, 2023. BAFNA PHARMACEUTICALS LTD. - 532989 - Closure of Trading Window
The "Trading Window" for the designated persons, connected persons, and their immediate relatives to deal in shares of the Company, shall remain closed from Friday, June 30, 2023, up to 48 hours after declaration of Audited Financial Results of the Company by the Board for the quarter ending June 30, 2023 (both days inclusive). The date of Board Meeting to consider and approve the aforesaid financial results of the Company will be intimated in the due course. BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of The Board Meeting Held On June 26, 2023.
Based on the recommendations of the Nomination and Remuneration Committee of Board of Directors, have interalia discussed and approved the appointment of following directors: 1. Mr. Vinayak Dinesh Dendukuri (DIN: 07601309) as Additional Director designated as Whole-time Director - Operation. 2. Mr. Upendar Mekala Reddy (DIN: 08898174) as Additional Director designated as Non-Executive Non-independent Director; 3. Mr. Krishna Yeachuri (DIN: 00066898) as Additional Director designated as Non-Executive Independent Director.